Hypolipidemic Agents

"Hypolipidemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.

Descriptor ID	D000960
MeSH Number(s)	D27.505.519.186.071 D27.505.954.557.500
Concept/Terms	Hypolipidemic Agents Hypolipidemic Agents Agents, Hypolipidemic Antihyperlipidemics Hypolipidemic Drugs Drugs, Hypolipidemic Antilipemic Drugs Drugs, Antilipemic Antilipemics Antihyperlipemics Antilipemic Agents Agents, Antilipemic

Below are MeSH descriptors whose meaning is more general than "Hypolipidemic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Antimetabolites [D27.505.519.186]
Hypolipidemic Agents [D27.505.519.186.071]
Therapeutic Uses [D27.505.954]
Lipid Regulating Agents [D27.505.954.557]
Hypolipidemic Agents [D27.505.954.557.500]

Below are MeSH descriptors whose meaning is related to "Hypolipidemic Agents".

Below are MeSH descriptors whose meaning is more specific than "Hypolipidemic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hypolipidemic Agents" by people in this website by year, and whether "Hypolipidemic Agents" was a major or minor topic of these publications.

Bar chart showing 52 publications over 20 distinct years, with a maximum of 6 publications in 2003 and 2006

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	0	1
2002	1	1	2
2003	4	2	6
2004	2	2	4
2005	2	1	3
2006	3	3	6
2007	0	1	1
2008	3	0	3
2009	1	2	3
2010	1	1	2
2011	2	1	3
2013	2	1	3
2014	2	0	2
2015	2	0	2
2017	1	2	3
2018	0	1	1
2019	3	1	4
2020	0	1	1
2022	0	1	1
2024	0	1	1

Below are the most recent publications written about "Hypolipidemic Agents" by people in Profiles.

Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, Gill EA, Jacobson TA, Michos ED, Safarova MS, Soffer DE, Taub PR, Wilkinson MJ, Wilson DP, Ballantyne CM. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024 May-Jun; 18(3):e308-e319.

View in: PubMed
Patrick WL, Khurshan F, Bavaria JE, Zhao Y, Groeneveld PW, Yarlagadda S, Rosen JL, Grimm JC, Szeto WY, Desai ND. National Adherence to Medical Management of Aortic Aneurysms. Am J Med. 2022 10; 135(10):1202-1212.e4.

View in: PubMed
Karalis DG. Editorial commentary: Advances in the management of dyslipidemia: The future is bright, but what we do today is what matters most. Trends Cardiovasc Med. 2021 10; 31(7):425-426.

View in: PubMed
Khan SU, Khan MU, Valavoor S, Khan MS, Okunrintemi V, Mamas MA, Leucker TM, Blaha MJ, Michos ED. Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials. Eur J Prev Cardiol. 2020 08; 27(12):1255-1268.

View in: PubMed
Li YR, Ro V, Steel L, Carrigan E, Nguyen J, Williams A, So A, Tchou J. Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer. Breast Cancer Res Treat. 2019 Aug; 176(3):669-677.

View in: PubMed
Wright AK, Kontopantelis E, Emsley R, Buchan I, Mamas MA, Sattar N, Ashcroft DM, Rutter MK. Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus. Circulation. 2019 06 11; 139(24):2742-2753.

View in: PubMed
Friedrich DA, Karalis DG, Aspry KE, Martin SS, Guyton JR. JCL roundtable: Lipid treatment targets. J Clin Lipidol. 2019 Mar - Apr; 13(2):223-230.

View in: PubMed
Robinson JG, Williams KJ, Gidding S, Bor?n J, Tabas I, Fisher EA, Packard C, Pencina M, Fayad ZA, Mani V, Rye KA, Nordestgaard BG, Tybj?rg-Hansen A, Douglas PS, Nicholls SJ, Pagidipati N, Sniderman A. Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. J Am Heart Assoc. 2018 10 16; 7(20):e009778.

View in: PubMed
Fink HA, Jutkowitz E, McCarten JR, Hemmy LS, Butler M, Davila H, Ratner E, Calvert C, Barclay TR, Brasure M, Nelson VA, Kane RL. Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review. Ann Intern Med. 2018 01 02; 168(1):39-51.

View in: PubMed
Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing. Circulation. 2017 Dec 05; 136(23):2210-2219.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement